Biowaivers

Biowaivers are regulatory exemptions granted for certain bioequivalence studies, allowing for the approval of generic drugs without conducting comparative clinical trials. They are typically based on the demonstration of similarity in the rate and extent of drug absorption between the generic and reference products using in vitro dissolution testing or other surrogate measures. Biowaivers are granted when the drug's pharmacokinetics are well understood, and there is a high likelihood of therapeutic equivalence, saving time and resources in drug development while maintaining patient safety and efficacy.

 

    Related Conference of Biowaivers

    February 24-25, 2025

    2nd International Conference on Pharmacognosy

    Madrid, Spain
    February 27-28, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    March 10-11, 2025

    35th Annual European Pharma Congress

    Rome, Italy
    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Aix-en-Provence, France
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Biowaivers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in